More on ENTA
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $13.45 |
|
|||
| Open | $13.51 | ||||
| 52 Wk High | $34.49 | ||||
| 52 Wk Low | $20.39 | ||||
| Day High | $14.25 | ||||
| Day Low | $13.43 | ||||
| P/E | N/A | ||||
| EPS | $-3.18 | ||||
| Volume | 938,110 | ||||
- Enanta Pharma loses appeal in Pfizer Paxlovid patent case
- Form 8-K ENANTA PHARMACEUTICALS For: Jun 23
- H.C. Wainwright Reiterates Buy Rating on Enanta Pharmaceuticals (ENTA)
- Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
- Form 8-K ENANTA PHARMACEUTICALS For: Jun 18
- Enanta advances RSV drug zelicapavir into late-stage trials
- Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
- Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
- Form S-8 ENANTA PHARMACEUTICALS
- Form 10-Q ENANTA PHARMACEUTICALS For: Mar 31
Entities mentioned with ENTA
- Earnings | View Related Stories »
- FDA | View Related Stories »
- 13G | View Related Stories »
- Twitter | View Related Stories »
- JPMorgan | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
